• 1
    Radich JP,Gehly G,Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995; 85: 26322638.
  • 2
    Druker B,Guilhot F,O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 24082417.
  • 3
    Kantarjian HM,Cortes JE,O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004; 104: 19791988.
  • 4
    Gratwohl A,Baldomero H,Horisberger B,Schmid C,Passweg J,Urbano-Ispizua A. Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002; 100: 23742386.
  • 5
    Giralt S,Sobocinski K,Horowitz MM. Impact of imatinib therapy on the use of allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of the chronic myeloid leukemia (CML). Blood. 2003; 102: 473a.
  • 6
    Gorre ME,Mohammed M,Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876880.
  • 7
    Hochhaus A,Kreil S,Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16: 21902196.
  • 8
    Branford S,Rudzki Z,Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102: 276283.
  • 9
    Golemovic M,Verstovsek S,Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005; 11: 49414947.
  • 10
    O'Hare T,Walters DK,Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005; 65: 45004505.
  • 11
    Kantarjian HM,Giles F,Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 25422551.
  • 12
    Shah NP,Tran C,Lee FY,Chen P,Norris D,Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399401.
  • 13
    Talpaz M,Shah N,Kantarjian HM, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 25312541.
  • 14
    Zaucha JM,Prejzner W,Giebel S, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005; 36: 417424.
  • 15
    Deininger M,Schleuning M,Greinix M, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006; 9: 452459.
  • 16
    Kantarjian HM,O'Brien S,Cortes JE, et al. Treatment ofPhiladelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8: 21672176.
  • 17
    Cortes J,Talpaz M,O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11: 34253432.
  • 18
    Przepiorka D,Smith TL,Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999; 94: 14651470.